Risk of declining sales following a sharp increase in demand for materials used in PCR diagnostic kits
First written in FY2021-Q1. 4 of 12 entries say "Materialised", first in FY2021-Q2. Latest entry: FY2024-Q3.
Hodogaya Chemical moved to the "Worse" side of this theme in 2020, 3 years before the typical company in this theme (2023).
The whole theme swung hardest in 2022: 5 of 8 companies on the "Worse" side.
1 other company's latest entry also says "Softened".
- FY2024-Q3SoftenedAnnual report
「Demand for materials used in PCR diagnostic kits supplied by a subsidiary remained weak, but increased demand for OLED materials, mainly in the smartphone display sector, together with the positive effect of foreign exchange movements on revenue, resulted in a substantial increase in revenue for the OLED materials business as a whole.」
Although demand for materials for PCR diagnostic kits remains sluggish, the business as a whole recorded a substantial increase in revenue, weakening the impact from the previous quarter's substantial decline in demand and decline in business revenue. - FY2024-Q2WorsenedAnnual report
「A substantial post-COVID decline in demand for materials for PCR diagnostic kits at our subsidiary was observed」
For materials for PCR diagnostic kits after the special demand, the decline in demand was described as a “substantial decline,” more severe than in the previous quarter, indicating that the impact of the risk continued. - FY2023-Q3MaterialisedAnnual report
「Demand during the previous fiscal year for materials for PCR diagnostic kits at our subsidiary for use with COVID-19 declined substantially」
The risk of declining sales of materials for PCR diagnostic kits after the special demand again materialised in the business situation as a substantial decline in demand during the previous fiscal year. - FY2023-Q2WorsenedAnnual report
「At our subsidiary, demand for materials for PCR diagnostic kits for COVID-19 declined substantially during the previous fiscal year, resulting in a decline in revenue for the OLED materials business as a whole.」
For materials for PCR diagnostic kits after the special demand, a substantial decline in demand was explicitly reported, and the impact of the risk continued as a decline in revenue for the OLED materials business as a whole. - FY2023-Q1MaterialisedAnnual report
「Demand for materials used in PCR diagnostic kits supplied by a subsidiary declined, but demand for OLED panels in the smartphone display sector continued to increase, leaving revenue for the OLED materials business as a whole at the same level as the previous year.」
For materials for PCR diagnostic kits, a decline in demand corresponding to the risk of declining sales after intensifying competition and the special demand was actually reported as the business situation for the current quarter. - FY2022RestatedAnnual report
「Special demand for materials for PCR diagnostic kits in the first quarter of the previous fiscal year subsided and sales declined, but stable sales continued during the current consolidated fiscal year.」
Although the risk of declining sales after the special demand remains, the description has settled on stable sales continuing during the current fiscal year. - FY2022-Q3SoftenedAnnual report
「Special demand in the first quarter of the previous fiscal year subsided, but stable sales have continued」
The company continued to report that sales remained stable after the special demand subsided, with regard to the risk of declining sales. - FY2022-Q2SoftenedAnnual report
「In the OLED materials business, special demand for materials for PCR diagnostic kits at our subsidiary subsided in the first quarter of the previous fiscal year, but stable sales have continued.」
Regarding the risk of declining sales after the special demand, the company reported that sales have continued steadily, indicating a weaker impact than the previous substantial decline in revenue after the special demand levelled off. - FY2022-Q1MaterialisedAnnual report
「Special demand related to COVID-19 in the previous fiscal year levelled off, resulting in a substantial decline in revenue for the OLED materials business as a whole.」
The risk of declining sales of materials for PCR diagnostic kits after the special demand levelled off actually materialised as a substantial decline in revenue for the OLED materials business as a whole. - FY2021-Q3SoftenedAnnual report
「Sales volume had declined during the second quarter due to intensifying competition, but has recently shown signs of a slight recovery as infections spread again globally.」
The decline in sales volume of materials for kits that became apparent in the second quarter was described as showing signs of a slight recovery recently, indicating a weaker manifestation of the risk. - FY2021-Q2MaterialisedAnnual report
「However, sales volume has recently declined due to increased supply resulting from intensifying global competition and other factors.」
The decline in sales of materials for PCR diagnostic kits anticipated as of the first quarter was actually reported as a recent decline in sales volume. - FY2021-Q1First statedAnnual report
「However, due to increased supply resulting from intensifying global competition and other factors, a substantial decline in sales of materials for PCR diagnostic kits is expected from the second quarter onward.」
Although demand for materials for PCR diagnostic kits surged during the current quarter, the risk of a substantial decline in sales from the second quarter onward due to intensifying global competition and increased supply was identified separately for the first time.